Voya Investment Management LLC Reduces Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Voya Investment Management LLC decreased its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 99.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,708 shares of the company's stock after selling 11,313,691 shares during the period. Voya Investment Management LLC's holdings in TransMedics Group were worth $730,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TMDX. Hsbc Holdings PLC grew its position in shares of TransMedics Group by 161.0% during the fourth quarter. Hsbc Holdings PLC now owns 87,498 shares of the company's stock worth $5,452,000 after acquiring an additional 53,970 shares during the last quarter. Stifel Financial Corp grew its position in TransMedics Group by 20.8% during the 4th quarter. Stifel Financial Corp now owns 8,968 shares of the company's stock worth $559,000 after purchasing an additional 1,544 shares during the last quarter. OneDigital Investment Advisors LLC acquired a new position in TransMedics Group in the fourth quarter valued at $245,000. State of Tennessee Department of Treasury purchased a new stake in shares of TransMedics Group in the fourth quarter valued at about $830,000. Finally, Tower Research Capital LLC TRC boosted its stake in shares of TransMedics Group by 1,602.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,359 shares of the company's stock worth $272,000 after buying an additional 4,103 shares during the period. Hedge funds and other institutional investors own 99.67% of the company's stock.

TransMedics Group Price Performance

Shares of TMDX traded up $18.30 during trading hours on Friday, reaching $111.50. The company had a trading volume of 4,541,391 shares, compared to its average volume of 1,348,071. The company has a market capitalization of $3.77 billion, a price-to-earnings ratio of 118.62 and a beta of 1.91. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37. The firm has a 50 day simple moving average of $78.53 and a 200-day simple moving average of $75.42. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.29 by $0.41. The company had revenue of $143.54 million during the quarter, compared to the consensus estimate of $123.39 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company's revenue for the quarter was up 48.2% on a year-over-year basis. During the same period last year, the firm earned $0.35 EPS. Research analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on TMDX. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research report on Wednesday, April 23rd. Oppenheimer boosted their target price on TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a report on Friday. Piper Sandler reaffirmed an "overweight" rating and set a $125.00 price target (up from $105.00) on shares of TransMedics Group in a report on Friday. Finally, Canaccord Genuity Group reissued a "buy" rating and issued a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $126.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.